Proactive Investors
29 Sept 2026, 07:34 UTC · 39m ago
Verdict
Headline takes no side. We score POLB +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 4 new · 0 priced in
Poolbeg Pharma has secured funding to complete both clinical programmes, with cash runway extending into Q2 2028.
Newpublished 29 Sep 2026
So whatThis eliminates the immediate need for dilutive equity raises for the next ~20 months.
More positive than 93% of claims this week
The company expects to launch a proof-of-concept study for its oral GLP-1 obesity treatment in the second half of the year.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Newpublished 29 Sep 2026
So whatEntering the high-growth GLP-1 market provides a second value driver alongside the POLB 001 cancer program.
More positive than 87% of claims this week
Safety data from the first six patients in the TOPICAL trial of POLB 001 recommended the trial continue without design changes.
Newreported 'Last week'
So whatPositive safety signals for the first 20% of the 30-patient cohort reduce the risk of early trial termination.
More positive than 79% of claims this week
The company reported a narrowed loss of £1.9 million for the first half of 2026, compared to £2.2 million in the prior period.
Newinterim results for H1 2026
So whatThe £300k reduction in losses was driven by a £700k drop in administrative costs despite higher R&D spend.
More positive than 46% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company has secured funding through to 2028, seen narrowing losses, and received positive safety data for its lead clinical program.
Near neutral — 92% of ticker scores this week are stronger
The company is mentioned only as the provider of a drug used in a trial for another company's product.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
43m ago
—
No price for POLB right now — the quote feed didn't answer.
POLB chart →
